The significance of FOXP1 in diffuse large B-cell lymphoma

The significance of FOXP1 in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of mature B-cell lymphoma. While the majority of patients are cured with immunochemotherapy incorporating the anti-CD20 monoclonal antibody rituximab (R-CHOP), relapsed and refractory patients still have a dismal prognosis. DLBCL subty...

Full description

Bibliographic Details
Main Authors:	Gascoyne, D, Banham, A
Format:	Journal article
Published:	Taylor and Francis 2016

Similar Items

Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
by: Banham, A, et al.
Published: (2005)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
by: Camilleri, E, et al.
Published: (2012)

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
by: Brown, P, et al.
Published: (2015)

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
by: Wong, K, et al.
Published: (2016)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
by: Wong, K, et al.
Published: (2014)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
by: Wong, K, et al.
Published: (2014)

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
by: Barrans, S, et al.
Published: (2004)

Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
by: Barrans, S, et al.
Published: (2007)

Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation.
by: Haralambieva, E, et al.
Published: (2006)

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
by: Nyman, H, et al.
Published: (2009)

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
by: Nyman, H, et al.
Published: (2008)

Strong expression of FOXP1 predicts for poor prognosis within the non-germinal centre subgroup of diffuse large B cell lymphoma
by: Barrans, S, et al.
Published: (2005)

FOXP3 expression in B and T cell lymphomas.
by: Roncador, G, et al.
Published: (2005)

t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.
by: Fenton, J, et al.
Published: (2006)

A new immunostain algorithm improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups
by: Choi, W, et al.
Published: (2008)

A new immunostain algorithm improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups
by: Choi, W, et al.
Published: (2008)

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
by: Brown, P, et al.
Published: (2016)

Is FOXP3 expressed in cutaneous T-cell lymphomas?
by: Banham, A, et al.
Published: (2008)

CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model
by: Felce, SL, et al.
Published: (2020)

The architectural pattern of FOXP3(+) T cells is an independent predictor of survival in patients with follicular lymphoma (FL)
by: Farinha, P, et al.
Published: (2006)

The architectural pattern of FOXP3*T cells is an independent predictor of survival in patients with follicular lymphoma (FL)
by: Farinha, P, et al.
Published: (2006)

Serologic detection of diffuse large B-cell lymphoma-associated antigens.
by: Liggins, A, et al.
Published: (2004)

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
by: Ait-Tahar, K, et al.
Published: (2009)

Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis
by: Jing Yang, et al.
Published: (2022-09-01)

PROGNOSTIC SIGNIFICANCE OF LMR AND RDW IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
by: CA Assis, et al.
Published: (2023-10-01)

Pathway activation patterns in diffuse large B-cell lymphomas.
by: Bentink, S, et al.
Published: (2008)

The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.
by: Brown, P, et al.
Published: (2005)

Diffuse large B-cell lymphoma
by: Gatter, K, et al.
Published: (2010)

Clinical Significance of Alk-1 Gene Abnormalities in Diffuse Large Cell Lymphoma
by: L. Korashy, et al.
Published: (2012-01-01)

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
by: Ait-Tahar, K, et al.
Published: (2009)

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
by: Hans, C, et al.
Published: (2004)

CLINICAL SIGNIFICANCE OF THE TP53 MUTATION STATUS IN DIFFUSE LARGE B-CELL LYMPHOMA
by: E. N. Voropaeva, et al.
Published: (2019-03-01)

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
by: Nyman, H, et al.
Published: (2009)

Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma
by: Kenneth C. Fan, et al.
Published: (2019-06-01)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
by: Ait-Tahar, K, et al.
Published: (2011)

The forkhead transcription factor FOXP2 is required for regulation of p21WAF1/CIP1 in 143B osteosarcoma cell growth arrest
by: Gascoyne, DM, et al.
Published: (2015)

Refractory diffuse large B-cell Lymphoma
by: Hajar Masrour, et al.
Published: (2023-01-01)

Diffuse Large B Cell Lymphoma of the Breast
by: Feryal Karaca, et al.
Published: (2015-03-01)

Transplant in Diffuse Large B-Cell Lymphoma
by: Guilherme Duffles, et al.
Published: (2022-06-01)

TRPM4 expression is associated with activated B-cell subtype and poor survival in diffuse large B-cell lymphoma
by: Loo, S, et al.
Published: (2017)